Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer

Trial Profile

A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABSK 112 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors Abbisko Therapeutics

Most Recent Events

  • 17 Jan 2024 Status changed from not yet recruiting to recruiting.
  • 07 Jul 2023 New trial record
  • 04 Jul 2023 According to Abbisko Therapeutic media release, the company announced that IND has been approved by FDA for this phase I clinical trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top